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Background: Multidrug- (MDR) and extensively drug resistant (XDR) tuberculosis (TB) presents a challenge to
disease control and elimination goals. In Lisbon, Portugal, specific and successful XDR-TB strains have been found in
circulation for almost two decades.
Results: In the present study we have genotyped and sequenced the genomes of 56 Mycobacterium tuberculosis isolates
recovered mostly from Lisbon. The genotyping data revealed three major clusters associated with MDR-TB, two of which
are associated with XDR-TB. Whilst the genomic data contributed to elucidate the phylogenetic positioning of
circulating MDR-TB strains, showing a high predominance of a single SNP cluster group 5. Furthermore, a genome-wide
phylogeny analysis from these strains, together with 19 publicly available genomes of Mycobacterium tuberculosis clinical
isolates, revealed two major clades responsible for M/XDR-TB in the region: Lisboa3 and Q1 (LAM).
The data presented by this study yielded insights on microevolution and identification of novel compensatory mutations
associated with rifampicin resistance in rpoB and rpoC. The screening for other structural variations revealed putative
clade-defining variants. One deletion in PPE41, found among Lisboa3 isolates, is proposed to contribute to immune
evasion and as a selective advantage. Insertion sequence (IS) mapping has also demonstrated the role of IS6110 as a major
driver in mycobacterial evolution by affecting gene integrity and regulation.
Conclusions: Globally, this study contributes with novel genome-wide phylogenetic data and has led to the identification
of new genomic variants that support the notion of a growing genomic diversity facing both setting and host adaptation.
Keywords: Whole genome sequencing, MDR-TB, XDR-TB, Lisboa family, MicroevolutionBackground
Tuberculosis (TB) is responsible for approximately 1.4
million deaths each year and is considered a Global
Health Emergency by the World Health Organization
(WHO). Portugal is the Western European country that
over the last few decades has had one of the highest TB
notification rates in Europe (24.7 cases per 100 000)
[1]. Although this rate is considered intermediate, the
difficulty is the growing threat of drug resistance. In par-
ticular, the two most difficult-to-treat forms: multidrug-* Correspondence: isabel.portugal@ff.ul.pt
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unless otherwise stated.resistance (MDR, resistance to the two most powerful
first-line drugs – isoniazid (INH), and rifampicin (RIF))
and extensive drug resistance (XDR, MDR plus resistance
to fluoroquinolones (FQ), and a second-line injectable
drug) [2,3].
The TB situation in the capital city, Lisbon (incidence
31.5 cases / 100 000 in 2010) has been extensively studied
[4-8]. Laboratory data on resistance prevalence point to
high XDR-TB rates in the region, which in recent years
have ranged between 44.3-66.1% of the MDR-TB clinical
isolates [9].Genotyping studies using IS6110 Restriction
Fragment Length Polymorphism (RFLP), Spoligotyping,
and more recently, through the characterization of Myco-
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ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Perdigão et al. BMC Genomics 2014, 15:991 Page 2 of 20
http://www.biomedcentral.com/1471-2164/15/991of Tandem Repeats (MIRU-VNTR), have led to the identi-
fication of a family of close genetic clusters in the 90’s: the
Lisboa family, highly associated with MDR- and now
XDR-TB [4,7,8].The Lisboa family has been defined a
group of strains/clusters sharing a similar RFLP-IS6110
profile (nine bands), belonging to the LAM lineage and/or
sharing a similarity rate of at least 95% when genotyped by
12-loci MIRU-VNTR [7,9]. The prevalence of this family
in the region may account to up to 74.0% and 80.0% of
MDR- and XDR-TB cases, respectively [4,5,9].
Another genetically close and endemic cluster, also be-
longing to the LAM lineage, named Q1 also plays an im-
portant role in MDR- and XDR-TB in the region and its
impact on public health and drug-resistant TB in the re-
gion has been addressed in previous publications [5,9].
When genotyped by 12-loci MIRU-VNTR, the Q1 cluster
strains have been shown to share 11 MIRU-VNTR loci al-
leles with the most important Lisboa cluster (Lisboa3) but
yet, bearing distinct mutational profiles on rpsL, rrs and
gyrA genes [5]. A characteristic deletion of spacers 38–43
in the Direct Repeat locus has also been observed along-
side with a characteristic spoligotyping LAM signature
(data not published). Recently, mutation A80P in the gidB
gene, responsible for low-level streptomycin (STP) resist-
ance, has been proposed as a marker for Q1 strains [10].
The etiologic agents of TB are the bacterial (sub)species
belonging to Mycobacterium tuberculosis complex (MTC),
such as Mycobacterium tuberculosis sensu stricto (M. tu-
berculosis) orMycobacterium bovis [11,12].M. tuberculosis
has been regarded for many years as a genetically mono-
morphic pathogen. Nevertheless, the high-throughput
genomic sequencing of diverse clinical strains has revealed
a higher degree of variation than initially anticipated
[13-16]. Next-Generation Sequencing (NGS) technology is
allowing new insights on the mode of transmission and
evolution of the MTC [17,18]. Furthermore, the ability to
compare, at the genomic level, identical strains in different
stages of resistance acquisition can also provide new data
on the genomic adaptation and compensation to the fix-
ation of resistance-associated mutations in the host’s ba-
cilli population [18,19].
In this regard, the genomic determinants of the Lisboa
family and Q1 strains are yet to be characterized. In the
present study, we have genotyped and sequenced the ge-
nomes of 56M. tuberculosis clinical isolates (sourced
from the Lisbon Health Region) with the aim of gaining
insights into the genomic diversity and microevolution
of prevalent MDR- and XDR-TB circulating strains in
the Lisbon region.
Results
Of 56M. tuberculosis isolates studied, 36 (64.3%) were
resistant to INH and RIF and were therefore classified as
MDR-TB isolates, of which we were able to determinethe resistance to second-line drugs for 24 isolates. In
total, 10 MDR-TB isolates were also classified as XDR-
TB (Table 1).
Genotypic analysis
The 24-loci MIRU-VNTR genotyping technique grouped
the MDR-TB isolates into three major clusters: Lisboa3-
A, Lisboa3-B and Q1 (Figure 1). Use of the 12-loci set
groups Lisboa3-A and -B in a single cluster (Lisboa3,
data not shown). Only the Lisboa3-B and Q1 clusters
were found to be associated with XDR-TB isolates. Eight
of the ten XDR-TB isolates belonged to either Lisboa3-B
or Q1 cluster, and one of remaining two strains was
found to be Q1-related, raising the possibility of ances-
tral Q1 XDR followed by posterior divergence from this
cluster. No XDR-TB isolate was found to belong to
Lisboa3-A cluster.
Genomic analysis
All 56 clinical isolates underwent whole genome sequen-
cing (WGS) The total number of identified SNPs (point
mutations differing from H37Rv) ranged between 488–
1465 (mean: 928.0, 26.7% in non-coding regions) (Table 1).
Of the SNPs on coding regions, 58.5% were considered
non-synonymous substitutions yielding a mean non-
synonymous/synonymous ratio (Ns/S) of 1.41 (Table 1).
AG, CT, GA and TC transitions were found to be the
most frequent substitution types (see Additional file 1),
which is reflected by a mean transversion/transition ratio
(Tv/Ts) of 0.62. Overall, across the 56 clinical isolates and
19 publicly available reference strains (F11, CDC1551,
KZN1435, KZN4207, KZN605, KZN_R506, KZN_V2475,
UT205, RGTB327, RGTB423, CCDC5180, CCDC5079,
CTRI-2, BTB05_552, BTB05_559, S96_129, HN878,
R1207, and X122), 9419 genome-wide SNPs were identi-
fied by mapping to the reference genome ofM. tuberculosis
H37Rv. The number of small insertions and deletions
(indels) detected upon read mapping ranged between
15–175 indels per isolate with a size between 1–59 bp
(Table 1).
Global phylogenetic analysis using WGS
Using WGS data, the 56 clinical isolates and 19 publicly
available strains were assigned into established six SNP
Clusters Groups (SCG) and three Principal Genetic
Groups (PCG) [14,20]. Overall, at least one isolate be-
longing to each SCG and subgroups was included in the
subsequent analysis. Forty-four (78.6%) of the 56 clinical
isolates belonged to SCG 5, reflecting the high preva-
lence of these strains in Lisbon Health Region (Table 1).
A phylogenetic tree was inferred from a set of 9419
genome-wide SNPs (Figure 2). It reveals that the two
main genetic clusters associated with XDR-TB in the re-
gion, Q1 and Lisboa3, constitute two genetically close
Table 1 Isolate characteristics: DST and data derived from WGS including mapping indicators
Isolate DSTa SCG PGG Spoligotypeb SNPs INDELsc Mapping
Indicatorsd
First-Line Second-Line SIT Clade Non-
synonymous
mutations
(Ns)
Synonymous
mutations (S)
Total in
Coding
Regions
(Tc)
Total in
Non-
Coding
Regions
Total Ns/S
Ratio
Tv/Ts
Ratio
Tc/
Total
Total Size
Range
Mean
Read
Depth
Coverage
(%)
ARS10348 IRS ETH 5 2 20 LAM1 410 296 706 243 949 1.3851 0.5865 0.7439 96 1-24 135.18 98.86
ARS11131 IRSP CAP AMK
OFX MOX
ETH
5 2 1106 LAM4 381 286 667 237 904 1.3322 0.6308 0.7378 95 1-24 101.56 98.89
ARS11285 IRS AMK OFX
MOX
4 2 119 X1 429 302 731 283 1014 1.4205 0.6031 0.7209 114 1-37 159.38 99.83
ARS11463 I nd 5 2 64 LAM6 382 255 637 241 878 1.4980 0.5575 0.7255 76 1-24 52.42 99.47
ARS11661 IS nd 5 2 1106 LAM4 378 284 662 234 896 1.3310 0.6443 0.7388 96 1-24 110.16 98.84
ARS12740 IRSP ETH 5 2 1106 LAM4 392 287 679 239 918 1.3659 0.6456 0.7397 95 1-24 97.66 98.81
ARS1717 IRP OFX ETH 6a 3 2258 Unknown 263 158 421 160 581 1.6646 0.5651 0.7246 67 1-27 68.89 99.76
ARS1760 I nd 5 2 64 LAM6 379 262 641 242 883 1.4466 0.5725 0.7259 83 1-53 69.23 99.40
ARS1900 IRSEP CAP KAN
OFX ETH
5 2 20 LAM1 414 301 715 250 965 1.3754 0.6009 0.7409 101 1-24 148.85 98.75
ARS1930 IRSP na 5 2 42 LAM9 389 268 657 228 885 1.4515 0.6158 0.7424 90 1-52 90.43 98.81
ARS2061 IRP CAP AMK
KAN OFX
ETH CS PAS
5 2 1106 LAM4 379 283 662 239 901 1.3392 0.6346 0.7347 89 1-24 80.51 98.83
ARS2202 IRSP OFX ETH CS 5 2 20 LAM1 404 284 688 243 931 1.4225 0.5889 0.7390 91 1-24 79.46 98.99
ARS2573 I nd 5 2 20 LAM1 400 277 677 231 908 1.4440 0.6250 0.7456 97 1-49 82.71 99.03
ARS3649 IRSEP KAN OFX
ETH
5 2 20 LAM1 399 282 681 242 923 1.4149 0.5814 0.7378 91 1-24 72.67 98.92
ARS3806 I nd 5 2 2535 Unknown 386 283 669 233 902 1.3640 0.6277 0.7417 85 1-24 195.56 98.84
ARS4857 IRP na 5 2 1106 LAM4 381 279 660 234 894 1.3656 0.6418 0.7383 92 1-24 91.12 98.86
ARS5858 IREP OFX 5 2 20 LAM1 395 284 679 243 922 1.3908 0.6401 0.7364 102 1-24 142.10 98.98
ARS6483 IRSEP OFX ETH 5 2 20 LAM1 406 303 709 246 955 1.3399 0.5839 0.7424 98 1-24 92.22 98.79
ARS6539 IS nd 5 2 20 LAM1 407 303 710 249 959 1.3432 0.5933 0.7404 63 1-24 273.98 98.87
ARS6559 I nd 5 2 81 LAM9 394 292 686 233 919 1.3493 0.5953 0.7465 86 1-24 63.55 98.76
ARS7496 IS nd 2 1 1 Beijing 589 410 999 405 1404 1.4366 0.6404 0.7115 175 1-39 109.62 99.30
ARS7571 I nd 5 2 211 LAM3 388 265 653 244 897 1.4642 0.5749 0.7280 93 1-24 123.02 99.48
ARS7860 IS nd 5 2 811 LAM4 378 279 657 232 889 1.3548 0.6318 0.7390 86 1-24 72.59 98.60
ARS7884 IRSEP OFX ETH 5 2 20 LAM1 409 300 709 244 953 1.3633 0.5874 0.7440 100 1-24 177.31 98.81
ARS8437 IRSP CAP ETH 5 2 20 LAM1 405 296 701 247 948 1.3682 0.6005 0.7395 92 1-24 179.07 98.78
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Table 1 Isolate characteristics: DST and data derived from WGS including mapping indicators (Continued)
ARS8600 I nd 5 2 20 LAM1 407 291 698 238 936 1.3986 0.6262 0.7457 74 1-49 254.44 98.97
ARS9427 I nd 3a 1 26 CAS1-
Delhi
632 411 1043 422 1465 1.5377 0.5773 0.7119 152 1-36 44.07 99.82
FF181_97 IRS na 5 2 20 LAM1 417 300 717 249 966 1.3900 0.6185 0.7422 24 1-9 772.29 98.99
FF291_98 IRS na 5 2 20 LAM1 416 294 710 250 960 1.4150 0.6063 0.7396 31 1-18 658.49 98.97
FF359_98 IRS na 5 2 20 LAM1 419 293 712 254 966 1.4300 0.5946 0.7371 31 1-18 836.93 99.01
FF674_96 Susceptible na 4 2 91 X3 428 323 751 276 1027 1.3251 0.6047 0.7313 34 1-33 961.69 99.76
HCC1095_10 IRE nd 3b 2 53 T1 429 314 743 292 1035 1.3662 0.5577 0.7179 119 1-24 185.45 99.61
HCC1276_11 IRSEP CAP AMK
OFX MOX
ETH
5 2 1106 LAM4 392 281 673 243 916 1.3950 0.6350 0.7347 96 1-24 159.36 98.81
HCC1470_11 IRSEP CAP AMK
KAN OFX
MOX ETH CS
PAS
5 2 20 LAM1 412 295 707 251 958 1.3966 0.5830 0.7380 99 1-24 96.90 98.76
HCC759_09 IR ETH 2 1 1 Beijing 623 414 1037 418 1455 1.5048 0.6102 0.7127 160 1-28 70.73 99.39
HCC916_10 IRSEP CAP AMK
KAN OFX
ETH
5 2 1106 LAM4 373 281 654 238 892 1.3274 0.6044 0.7332 103 1-24 145.85 98.82
HPV105_09 S nd 5 2 1752 LAM1 400 281 681 244 925 1.4235 0.6214 0.7362 37 1-22 591.50 98.93
HPV113_08 IRSEP ETH 6a 3 54 MANU2 222 126 348 140 488 1.7619 0.5945 0.7131 62 1-24 167.28 99.94
HPV115_08 IRSEP CAP AMK
KAN OFX
ETH
5 2 1106 LAM4 312 225 537 196 733 1.3867 0.7318 0.7326 76 1-21 179.43 98.82
HPV157_06 IS nd 5 2 17 LAM2 397 287 684 248 932 1.3833 0.5760 0.7339 90 1-24 96.25 98.87
HPV50_09 Susceptible nd 5 2 20 LAM1 397 291 688 238 926 1.3643 0.6554 0.7430 69 1-24 281.12 98.94
HPV51_09 Susceptible nd 3c 2 137 X2 420 309 729 276 1005 1.3592 0.5677 0.7254 29 1-18 632.88 99.60
HPV65_08 Susceptible nd 6a 3 Unknown Unknown 247 160 407 162 569 1.5438 0.5837 0.7153 15 1-18 1149.11 99.57
HPV70_09 Susceptible nd 5 2 1803 LAM1 380 277 657 224 881 1.3718 0.6343 0.7457 26 1-45 1410.21 99.65
HVNG1 IRSEP CAP AMK
KAN
5 2 20 LAM1 308 225 533 201 734 1.3689 0.7082 0.7262 76 1-24 154.30 98.78
IHMT134_09 IRSP RFB ETH 5 2 20 LAM1 332 228 560 203 763 1.4561 0.6935 0.7339 83 1-24 171.49 98.77
IHMT149_09 IRSEP RFB CAP
AMK OFX
MOX ETH
5 2 1106 LAM4 313 226 539 193 732 1.3850 0.6849 0.7363 75 1-21 168.54 98.81
IHMT194_11 IRSEP RFB CAP
AMK ETH
5 2 1106 LAM4 382 274 656 236 892 1.3942 0.6318 0.7354 83 1-24 47.61 98.96
IHMT288_95 IRSP RFB ETH 5 2 20 LAM1 415 304 719 247 966 1.3651 0.6230 0.7443 98 1-24 197.48 98.84
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Table 1 Isolate characteristics: DST and data derived from WGS including mapping indicators (Continued)
IHMT295_08 IRSEP RFB ETH 2 1 1 Beijing 528 337 865 358 1223 1.5668 0.7284 0.7073 127 1-59 181.48 99.18
IHMT308_08 IRP RFB ETH 5 2 1106 LAM4 334 228 562 201 763 1.4649 0.7524 0.7366 76 1-21 205.47 98.79
IHMT359_03 R nd 5 2 Orphan LAM1 406 289 695 247 942 1.4048 0.6276 0.7378 31 1-22 727.91 98.93
IHMT361_08 IREP CAP ETH 5 2 1106 LAM4 305 232 537 193 730 1.3147 0.6278 0.7356 70 1-24 191.20 98.80
IHMT69_11 IRSEP RFB CAP
AMK ETH
2 1 1 Beijing 609 420 1029 415 1444 1.4500 0.6307 0.7126 169 1-39 202.92 99.36
IHMT80_11 IRSEP RFB CAP
AMK ETH
5 2 1106 LAM4 380 277 657 236 893 1.3718 0.6318 0.7357 87 1-24 63.98 98.95
IHMT82_09 IRS RFB CAP ETH 5 2 20 LAM1 313 221 534 190 724 1.4163 0.6808 0.7376 81 1-24 121.47 98.69
aFirst-Line: I - Isoniazid, R - Rifampicin, S - Streptomycin, E - Ethambutol, P - Pyrazinamide; Second-Line: ETH - Ethionamide, KAN - Kanamycin, AMK - Amikacin, OFX - Ofloxacin, MOX - Moxifloxacin, RFB - Rifabutin, PAS -
Para-amino salicylic acid, CS - Cycloserine.
bSpoligotype inferred from SpolPred software (Coll et al., [89]).
cSmall INDELs called by SAMtools from mapping to M. tuberculosis H37Rv.
dRelative to M. tuberculosis H37Rv.
na, Not available.
nd, Not done.
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0.1
FF181_97 IRS na2 4 4 2 1 3 2 3 2 3 2 4 1 1 6 1 4 3 5 3 2 8 2 2
FF291_98 IRS na2 4 4 2 1 3 2 3 2 3 2 4 1 1 6 1 4 3 5 3 2 8 2 2
FF359_98 IRS na2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
FF674_96 2 2 3 2 4 4 3 2 2 2 3 4 4 2 4 1 5 3 3 3 3 3 0 2
ARS10348 IRS ETH2 4 4 2 1 3 2 3 2 3 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS11131 IRSP CAP AMK OFX MOX ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
ARS11285 IRS AMK OFX MOX2 2 3 2 5 3 3 4 2 3 3 4 4 2 5 1 5 3 3 3 5 5 3 2
ARS11463 I1 3 2 2 4 2 3 3 2 2 4 4 1 1 6 1 5 3 3 2 3 7 2 2
ARS11661 IS2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
ARS12740 IRSP ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
ARS1717 IRP OFX ETH2 2 2 2 3 5 4 2 2 1 2 4 2 2 5 1 5 3 3 3 4 5 2 2
ARS1760 I1 3 4 2 4 2 3 3 2 1 2 4 1 2 6 1 5 3 3 2 2 5 2 2
ARS1900 IRSEP CAP KAN OFX ETH2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS1930 IRSP na2 5 4 2 1 4 2 3 2 4 2 4 1 1 6 1 5 3 5 3 3 8 2 2
ARS2061 IRP CAP AMK KAN OFX ETH CS PAS2 4 4 2 1 2 1 3 2 3 2 4 1 1 4 1 6 2 5 3 2 8 2 2
ARS2202 IRSP OFX ETH CS2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS2573 I2 4 4 2 1 3 2 3 2 2 2 5 1 2 6 1 8 3 1 3 2 4 2 2
ARS3649 IRSEP KAN OFX ETH2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS3806 I2 4 4 2 1 2 1 3 2 4 2 4 1 1 4 1 4 2 5 3 2 7 2 2
ARS4857 IRP na2 4 4 2 1 3 1 3 2 3 2 4 1 1 5 1 4 2 5 3 2 8 2 2
ARS5858 IREP OFX2 1 4 2 1 3 2 3 2 2 2 5 1 2 7 1 5 3 3 3 2 4 2 2
ARS6483 IRSEP OFX ETH2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS6539 IS2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS6559 I2 4 4 2 1 4 2 3 2 3 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS7496 IS2 4 4 2 3 3 3 4 2 6 4 4 4 2 5 1 6 3 3 5 3 7 2 3
ARS7571 I2 3 2 2 3 3 2 3 2 4 2 3 2 2 6 1 5 3 1 3 1 9 2 2
ARS7860 IS1 4 4 2 1 2 1 3 2 3 2 4 1 1 6 1 3 1 5 3 2 9 2 2
ARS7884 IRSEP OFX ETH2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS8437 IRSP CAP ETH2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
ARS8600 I2 4 4 2 1 3 2 3 2 2 2 5 1 2 6 1 7 3 3 3 2 4 0 2
ARS9427 I2 4 2 2 3 3 5 4 2 2 4 4 2 2 5 1 6 3 2 3 3 8 3 3
HCC1095_10 IRE nd2 2 3 2 3 5 3 2 1 4 3 2 4 2 4 1 5 3 3 3 3 7 2 2
HCC1276_11 IRSEP CAP AMK OFX MOX ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
HCC1470_11 IRSEP CAP AMK OFX MOX ETH CS PAS2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
HCC759_09 IR ETH2 4 4 2 3 3 2 5 2 4 4 4 4 2 5 1 7 3 3 5 3 8 2 3
HCC916_10 IRSEP CAP AMK KAN OFX ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
HPV105_09 S2 1 4 2 1 3 2 2 2 2 2 5 1 2 6 1 5 3 3 3 2 4 2 2
HPV113_08 IRSEP ETH2 4 4 2 3 3 3 5 2 6 4 4 4 2 5 1 7 3 3 1 3 7 2 3
HPV115_08 IRSEP CAP AMK KAN OFX ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
HPV157_06 IS2 4 4 2 1 3 1 3 2 2 1 4 1 1 5 1 6 3 3 2 2 6 2 2
HPV50_09 susceptible2 1 4 2 1 3 2 3 2 2 2 5 1 2 6 1 5 3 3 3 2 2 2 2
HPV51_09 susceptible2 1 4 2 3 4 3 4 2 3 3 4 4 2 5 1 5 3 3 3 6 9 0 2
HPV65_08 susceptible2 2 4 2 2 3 3 2 1 5 3 4 2 2 5 1 5 3 3 3 3 5 2 2
HPV70_09 susceptible2 4 4 2 1 4 2 3 2 3 2 4 1 1 6 1 5 3 5 3 2 4 2 2
HVNG1 IRSEP CAP AMK KAN2 1 4 2 1 3 1 3 2 2 2 5 1 2 6 1 5 3 3 3 2 4 2 2
IHMT134_09 IRSP RFB ETH2 4 4 2 1 3 2 3 2 3 2 4 1 1 6 1 4 3 5 3 2 8 2 2
IHMT149_09 IRSEP RFB CAP AMK OFX MOX ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
IHMT194_11 IRSEP2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
IHMT288_05 IRSP2 4 4 2 1 3 2 3 2 3 2 4 1 1 6 1 4 3 5 3 2 8 2 2
IHMT295_08 IRSEP2 4 4 2 3 3 3 5 2 6 4 4 4 2 5 1 7 3 3 5 3 7 2 3
IHMT308_08 IRP2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
IHMT359_03 R nd2 1 4 2 1 3 2 3 2 2 2 5 1 2 6 1 6 3 3 3 2 4 2 2
IHMT361_08 IREP CAP ETH2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
IHMT69_11 IRSEP2 4 4 2 3 3 3 4 2 6 2 4 4 2 5 1 6 3 3 5 3 7 2 3
IHMT80_11 IRSEP2 4 4 2 1 3 1 3 2 3 2 4 1 1 4 1 4 2 5 3 2 8 2 2
IHMT82_09 IRS RFB CAP ETH2 4 4 2 1 3 2 3 2 4 2 4 1 1 6 1 4 3 5 3 2 8 2 2
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Figure 1 MIRU-VNTR genotypic analysis of the 56M. tuberculosis isolates. MIRU-VNTR dendrogram of the 56M. tuberculosis clinical isolates
subjected to WGS. First-line drug susceptibility testing: I, INH; R, RIF; S, STP; E, EMB; P, PZA. Second-line drug susceptibility testing: KAN, kanamycin;
AMK, amikacin; CAP, capreomycin; OFX, ofloxacin; MOX, moxifloxacin; ETH, ethionamide; PAS, para-amino salicylic acid; CS, cycloserine; na, not
available, nd, not determined.
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Lisboa3-A cluster was found to form a monophyletic group
within the Lisboa3 clade. The MIRU-VNTR Lisboa3-B
clade designation was therefore considered as paraphyletic
in the light of a genome-wide SNP phylogeny. The se-
quenced strain closest to the Lisboa3-Q1 clade is M. tuber-
culosis UT205, a virulent Colombian isolate that according
with the present phylogeny shares a more recent common
ancestor with Q1 strains than these do with Lisboa3 strains.
Global evolution through large sequence polymorphisms
Genomes in the M. tuberculosis complex can downsize,
through Large Sequence Polymorphisms (LSP) or Re-
gions of Difference (RD), and 89 have been previously
identified [21-23]. Across the 75 isolates, 29 (of 89) were
detected as absent in at least one isolate (see Additional
file 2). The most prevalent RDs detected were RD149
(64 isolates), RD152 (45), RD174 (43), RD3 (64), RD6
(54) and RDRIO (43). As expected, all 43 strains bearing
the RD174 (LAM) deletion also had the RDRIO deletion
[24]. Both deletions constitute a distinct sub-lineage
within the Euro-American lineage [23] and were de-
tected only among SCG 5 strains. UT205, like the Q1
and Lisboa 3 samples, had both deletions, confirming its
phylogenetic proximity with these M/XDR associated
strains (see Additional file 2).
All nine isolates from the SCG 2 had the RD105 dele-
tion characteristic of the East-Asian clade. Of these,other RD deletions were present (RD207 9 isolates,
RD181 8, RD142 2). Moreover, other RD deletions asso-
ciated with specific lineages were detected: RD750
(East-African-Indian lineage, SCG 3a, 1 isolate), RD115
(Euro-American lineage, Americas-Europe sublineage,
SCG 5, 8), RD183 (Euro-American lineage, Americas-
Europe sublineage, SCG 3c, 1) RD193 (Euro-American
lineage, Americas-Europe sublineage, SCG 4, 3), RD219
(Euro-American lineage, Americas-Europe sublineage, SCG
6a, 3), RD761 (Euro-American lineage, South Africa subli-
neage, SCG 5, 1 (F11 strain)) and RD724 (Euro-American
lineage, Central Africa sublineage, SCG 5, 3).
No RD region was found to be absent in RGTB423 and
only RDRIO deletion was detected in RGTB327. Strain
RGTB423 has been found to belong to SCG 1 and PGG 1
[25], but in-silico PCR analysis showed that the strain had
the pks15/1 7 bp frameshift deletion and the TbD1 dele-
tion indicative of a modern Euro-American strain [23].
Nevertheless, this classification is incongruent with the
SCG and PGG classification [11]. On the other hand,
RGTB327 was found to have the RDRIO deletion only and
in silico PCR of the pks15/1 and TbD1 loci also pointed
towards a modern Euro-American strain, despite the fact
that deletion RD174 was not detected. Further sequencing
of these two assembled strains may be required to resolve
incongruences.
Other structural variants were also searched employ-
ing different methodologies (see Additional files 3, 4, 5,
0.02
A B
Figure 2 M. tuberculosis genome-wide SNP-based phylogeny. Phylogenetic tree (A) and cladogram (B) of the initial 56 clinical isolates plus
20M. tuberculosis public genomes. PGGs are highlighted in green (PGG1), blue (PGG2) and red (PGG3). A - Isolate-depicting symbols are representative of
the different SCGs found in the tree: SCG 1 (yellow square), SCG 2 (black squares), SCG 3a (green triangle), SCG 3b (red triangle), SCG 3c (blue triangle), SCG
4 (black triangles), SCG 5 (circles), SCG 6a (green diamonds), SCG 6b (red diamond). Lisboa3 and Q1 strains are represented by red and blue circles (within
SCG 5), respectively.
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mentary material we highlight characteristic deletions
for the Lisboa3 clade and the ARS6559 isolate (complete
Lisboa3 subtree in Figure 3) (112 bp, position 2727803,
PPE41 gene), as well as the Q1 clade strains (297 bp,
position 3929891, ORF PE_PGRS53). Both deletions
were also validated by mapping coverage, but further la-
boratory confirmation is required.
Microevolution towards multidrug and extensively drug
resistance
Given the relative high number of sequenced strains
present in both Lisboa3 and Q1 clades it was possible to
trace the microevolutionary path reflecting the genomic
changes accompanying the resistance acquisition process.
We considered the subtrees containing the Lisboa3 and
Q1 clades plus one or two strains for the Lisboa3 and Q1subtrees, respectively, included as outgroups for the ensu-
ing analysis (Figure 3). In particular, we inferred the
changes in candidate resistant gene mutations at the nodes
of the trees.
The Lisboa3 subtree, including the outgroup strain
ARS6559, was found to be characterized by a 5 bp dele-
tion on the iniA gene. There is a common acquisition of
high-level INH resistance through a inhA double muta-
tion (in node B). The data also reflect the acquisition of
RIF resistance in three separate occasions, twice in the
Lisboa3-B strains by a rpoB S450L (equivalent to E. coli
S531L) and in Lisboa3-A lineage by a rpoB D435V
(equivalent in E. coli to D516V). Acquisition of XDR can
be seen in the two branches: the first by acquisition of
an eis G-10A, gyrA S91P and tlyA Ins755GT mutations
(node B1); and, by an eis G-10A and gyrA D94G muta-
tions (node E1). EMB resistance is likely to have been
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Figure 3 Microevolution from susceptible TB towards MDR- and XDR-TB. Lisboa3 (A) and Q1 (B) subtree cladograms highlighting the
microevolutionary path towards MDR and XDR within these two phylogenetic clades. Mutations acquired in genes associated with first and
second-line drug resistance are shown in branch or associated node.
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The latter mutation has been previously reported in one
EMB resistant isolate [26]. PZA resistance was found to
be acquired on multiple independent occasions through
pncA mutations.
The Q1 subtree included two other Q1-related strains
as outgroups. Here, it is possible to distinguish the ac-
quisition of INH low-level resistance by an inhA C-15 T
mutation (node B) from the acquisition of a higher INH
resistance level by an inhA missense mutation (I194A,
node C) [27]. Some of the isolates present in the subtree
were found outside the Q1 MIRU-VNTR cluster, but
share more recent common ancestors with other strainsFigure 4 Mapping of IS6110 insertion sites. Genomic distribution of tot
among Lisboa3 and Q1 isolates. Lisboa3 core and Q1 lanes depicts all inse
respectively. Lisboa3 node B1 comprises a XDR-TB lineage shown here with
three additional IS6110 copies when compared with the Lisboa3 core.in the clade, potentially indicating subsequent MIRU-
VNTR divergence. The Q1 clade has, therefore, been de-
fined as all isolates bearing the gidB A80P mutation
characteristic of this cluster and associated with STP
intermediate-level resistance previously described by
some of us [10]. A more linear resistance acquisition
dynamic was found for this clade. EMB resistance was
acquired on two possible occasions, through an embB
M423T (node C) and M306V (node D) mutations. RIF re-
sistance development, leading to MDR-TB, was found to
be acquired by a rpoB S450L mutation (node D), although
a second mutation on rpoB (L731P) was later developed
(node E). Resistance to PZA, injectable second-line drugsal mapped IS6110, intra and intergenic, and insertion sites found
rtion sites that are common to all Lisboa3 and Q1 clade isolates,
an extra IS6110 copy. Lisboa3-A (node D1) are shown here to bear
Table 2 Candidate RIF resistance compensatory
mutations found in RpoA, RpoB, and RpoC among
RIF-resistant isolates with other RIF resistant associated
mutations in RpoB
Protein Mutation SCG No. of Isolates SIFT Score
RpoA E184D 2 1 0.09
RpoB P45A 5 1 0.01
RpoB T328N 2 1 0.03
RpoB L452P 5 2 0.00
RpoB V496A 6a 1 0.10
RpoB D634G 5 1 0.49
RpoB L731P 2, 5 13 0.00
RpoB E812G 2 1 0.08
RpoB I1106T 5 2 0.00
RpoC G442C 5 1 0.00
RpoC W484G 2 1 0.00
RpoC D747G 4 1 0.35
RpoC K1152Q 5 4 0.00
RpoC S1287L 6a 1 0.23
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node D), rrs (A1401G, node F) and gyrA (D94A, node G),
respectively. Interestingly, isolates IHMT308_08 and
IHMT361_08 did not show the two latter mutations in rrs
and gyrA genes, and therefore inconsistent with both
strains positioning in the Q1 subtree.
A further observation is that M/XDR development in
the Lisboa3 subtree appeared to be accompanied by a
higher genomic diversification, translated in the number
of SNPs and small indels (Additional files 9 and 10).
This observation is probably in line with an earlier emer-
gence of the Lisboa3 clade and prolonged circulation in
the community leading to a higher intra-clade diversity
when compared to Q1 strains. Moreover, isolates from
the Lisboa3 and Q1 clades were found to bear a mean
proportion of 0.73% (range: 0.2-1.8%) and 0.85% (range:
0.2-1.6%) unique SNPs, respectively, in comparison with
the total SNP count of each strain. Both clades were
found to share a pool of 654 (67.7-90.3%) and 626 (68.2-
85.2%) common SNPs, respectively (Additional file 11).
This intra-cluster degree of genomic uniqueness is com-
parable with the data reported by Niemann et al. for the
comparison of two Beijing isolates from the same out-
break clone [13].
Mutational compensation for RIF-resistance
The acquisition of compensatory mutations following
resistance development has been proposed as a possible
mechanism to reduce the fitness cost carried by drug
resistance [28]. More recently, rpoA and rpoC genes
were found to harbor putative RIF resistance compensa-
tory mutations [18,29,30]. The microevolutionary analysis
of Lisboa3 and Q1 clades led to the identification of two
possible compensatory mutations in rpoC (K1152Q, node
B to B1 in the Lisboa3 subtree; see Additional file 12) and
rpoB (L731P, node D to E in the Q1 subtree; see Add-
itional file 13) leading to RIF resistance acquisition. The
rpoA and rpoC genes were screened for mutations in all
isolates. On the overall 13 different non-synonymous mu-
tations were found, of which only 6 occurred among
MDR/RIF-resistance isolates (Table 2). The impact on
protein function was inferred by computation of SIFT
scores [31]. Only three mutations occurring in rpoC (see
Additional file 14) were predicted to affect protein func-
tion with SIFT scores equal to 0.00, resulting from the
comparison of 189 sequences represented at each position
(Table 2). The remaining mutations were predicted to be
tolerated and yielded higher SIFT scores (>0.05), resulting
from the comparison of 171–189 sequences representing
each position tested (Table 2).
We also screened the remaining RNA polymerase sub-
units, RpoB and RpoZ, but only eight non-synonymous
mutations were identified in RpoB, concomitantly with
other RIF resistance associated mutations in RpoB (Table 2).Five RpoB mutations (P45A, T328N, L452P, L731P and
I1106T) were predicted to affect protein function after SIFT
score analysis (SIFT score <0.05) (Table 2).
Insertion sequence (IS) mapping and functional
consequences for genomic stability
Transposition events from ISs can have a profound effect
on strain physiology given the possibility of interference
with gene expression by ORF knock-out or gene upregula-
tion resulting from upstream transposition [32,33]. For all
strains included in the phylogenetic analysis, we attempted
to map the site of all ISs annotated as mobile elements in
the genome of M. tuberculosis H37Rv, namely IS6110.
Some complex inversions were found to be predominantly
transpositional events from multi-copy mobile-elements,
such as IS6110. The analysis revealed the presence of
IS6110, IS1081, IS1547, IS1557 and IS1558 in multiple
copies, but differing in size or annotated sequence at both
extremities. For this reason these ISs have been excluded
from the mapping analysis.
Variability was only observed for IS1561 and IS1532
(Additional file 15). As expected, IS1561 was not detected
in all isolates bearing the RDRIO deletion, whereas IS1532
is absent in isolates bearing the RD6 deletion found on dif-
ferent SCGs. For IS6110, a total of 251 candidate insertion
sites have been obtained (Additional file 16), classified as
of high (160), medium (18) or lesser (73) confidence.
Almost half (125 (49.8%)) of the 251 ISs were observed on
the positive strand. A total of 105 (41.8%) insertion sites
were found to be intergenic, from which 64 (25.5%) were
in the same orientation with an upstream ORF, known to
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tion sites the distance from the 3′ end to the upstream
ORF ranged between 0–939 bp (47 (18.7%) less than
300 bp). Thirty-three sites were found to be within PE/
PPE genes, while three other insertion sites were located
18–38 bp upstream of a PPE gene.
Lisboa3 and Q1 clades were found to share 7 IS6110
sites but were differentiated by IS6110 insertions on po-
sitions 889015 (intergenic) and 4183431 (Rv3732 knock-
out) for Lisboa3 and, on 2582457 (intergenic) for Q1
isolates (Figure 4). Moreover, we have found that strains be-
longing to Lisboa3-A MIRU-VNTR cluster (rpoB D435V
clade on Figure 3-A) share three distinct IS6110 insertion
sites on Rv1682 (position 1906425), Rv2818c (position
3125900) and Rv3096 (position 3465467). Strains from the
XDR-TB Lisboa3 B1 clade (Figure 3-A) share a distinctive
IS6110 site on the plcC gene (position 2628462). Although
no common IS6110 site was found for the SCG 5 strains,
SCG 2 strains were found to share three IS6110 sites: an
intergenic site on position 888786; on Rv1754c (position
1986639); and, on Rv2820c (position 3127931). SCG 4
strains were found to also share three IS6110 sites on
mmpS1 (position 483580), PPE46 (position 3377326) and
PPE47 (position 3379768). One hundred and fifty-three
(60.0%) sites were found to be specific to a single isolate.
Interestingly, an IS6110 insertion in the NTF locus (pos-
ition 3493907) was detected in six out of the eight Beijing
strains included in the analysis, which is a characteristic of
the Beijing/W family [34,35] (Additional file 16). Hence,
two of the three Beijing isolates recovered in Lisbon Health
Region were found to belong to the Beijing/W family. No
relation with the New York City Beijing/W MDR clade
was found as a second insertion in the NTF locus was not
detected in any strains [34,35]. Curiously, a SCG 6a strain
(HPV113_08) shared the latter insertion site with the
Beijing/W strains, although only one end was detected
which can be indicative of another genomic rearrange-
ment. A SCG5 strain (HPV157_06) was found to have an
IS6110 67 bp upstream of the characteristic IS6110 inser-
tion site of the Beijing/W family, however in a different
orientation. Both insertion sites are found within Rv3128c.
This latter gene has an in-frame amber nonsense mutation
in H37Rv and for this reason any functional consequence
of IS6110-mediated ORF disruption is highly questionable.
Strains belonging to PGG2 were found to have a sig-
nificantly lower number of IS6110 copies when com-
pared with PGG1 strains (Kruskal-Wallis test, p <0.001).
Given the reduced number of PGG3 strains no statistical
comparison was possible to perform.
Differential substitution ratios highlight different genomic
adaptation strategies
A statistically significant difference in the Ns/S ratio was
observed between Lisboa3/Q1 and Beijing strains andothers, but only the Lisboa3 and Q1 result met a
multiple comparison threshold (Additional file 17). The
only significant Tv/Ts ratio difference occurred for differ-
ences between Lisboa3 and Q1 clusters (Q1 greater,
mean difference: 0.045, p =0.033) (Additional file 17).
These ratios were also found to vary across the gen-
ome and across the different Clusters of Orthologous
gene Groups (COGs). For each strain, we have com-
puted the Ns/S and Tv/Ts ratio for the different genomic
quadrants and for each COG. Overall quadrant Ns/S and
Tv/Ts comparison, showed that Ns/S ratio varied along
the chromosome such that the second quadrant had a
lower Ns/S ratio when compared with the other three
quadrants and that the first quadrant had the highest
Ns/S mean ratio (Kruskal-Wallis, p <0.001) (Additional
file 18). No statistical difference was observed between
the third and fourth quadrant. Regarding the Tv/Ts ratio,
an approximately inverse situation was found as no stat-
istical difference was observed between the first, third
and fourth quadrants. The second quadrant showed
however, a significantly higher Tv/Ts ratio than the three
other quadrants (Kruskal-Wallis, p <0.001) (Additional
file 18).
When these results were stratified by genetic clade, it
was found that in the first quadrant the Beijing strains
showed a statistically lower Ns/S ratio upon comparison
with Q1 and other non-clustered (NC) strains, but not
Lisboa3 (Additional file 19). No statistical difference was
found in this quadrant for Tv/Ts ratio. In the second
quadrant, Lisboa3 strains showed a statistically signifi-
cant reduced Ns/S ratio compared with the other three
groups of strains, while Beijing strains presented a
higher Ns/S ratio than the remaining groups (Additional
file 19). Inversely, the Tv/Ts ratio on the second quadrant
was significantly higher for Beijing strains when com-
pared to Q1 and other NC strains, but not to Lisboa3
strains (Additional file 19). The analysis of the third
quadrant showed no statistical difference for Ns/S ratio
while Beijing strains showed a higher Tv/Ts ratio on
comparison with Lisboa3 and other NC strains, but not
Q1 strains. Lisboa3 strains showed a reduced Tv/Ts ratio
on this latter quadrant when compared to all other groups.
In the fourth quadrant, only a statistical difference was
observed for a Q1 reduced Ns/S ratio when comparing
with the other strain groups and no significant difference
was observed for the Tv/Ts ratio (Additional file 19).
These results show that the Ns/S and Tv/Ts ratio mea-
sures appear to vary on a strain and chromosome region
dependent mode. Data stratification by isolate and
quadrant showed that the Tv/Ts ratio was found to
correlate negatively with the Ns/S ratio (Pearson, p
<0.001). Correlation between overall isolate Ns/S and
Tv/Ts ratio was also attempted but no correlation was
found (Pearson, p =0.433).
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different COGs also yielded strain dependent results. On
comparison with the other three strain groups: Lisboa3
strains showed higher Ns/S ratios on COG groups D (Cell
Cycle Control, Mitosis and Meiosis) and P (Inorganic Ion
Transport); Q1 strains showed higher Ns/S ratios on COG
group V (Defense Mechanisms); and, Beijing strains
showed higher Ns/S ratios on COG groups F (Nucleotide
Transport and Metabolism), K (Transcription), N (Cell
Motility), O (Post translation Modification, Protein turn-
over and Chaperones) and Q (Secondary Metabolites Bio-
synthesis, Transport and Catabolism) (Additional file 20).
Regarding the Tv/Ts ratio no significant difference was ob-
served for Lisboa3 strains, but higher ratios were observed
for Q1 strains in COG groups J (Translation), L (Replica-
tion, Recombination and Repair), M (Cell Wall, Mem-
brane Biogenesis) and, for Beijing strains in COG group C
(Energy Production and Conversion) (Additional file 21).
These results support the notion of a differential mode
of evolution and adaptation to the human host by accumu-
lation/selection of a higher degree of non-synonymous mu-
tations at genes belonging to specific functional categories.
According to recent work by Namouchi et al. [36], the
Ns/S ratio varied along the phylogenetic tree, such that
terminal branches had a higher Ns/S ratio than inner
branches. We have computed the Ns/S and Tv/Ts ratio
for the inner nodes assigned in the subtrees in Figure 4
and compared with the respective ratios calculated for
the tips of the subtrees. Contrary to the data of Namou-
chi et al. [36] we have verified that both subtrees had ≈
6% and ≈ 12% lower Ns/S ratios at the tips of Lisboa3
and Q1 subtrees, respectively, when compared with the
inner nodes of the tree (Independent t-test, p <0.001).
For the Tv/Ts ratio, the opposite was found: higher Tv/Ts
ratios were observed at the tips in comparison with the
inner nodes (Mann–Whitney test, p <0.001).
Discussion
M. tuberculosis genomic distinctiveness in Lisbon
For at least two decades the Lisbon Health Region in
Portugal has been characterized by a high-level of drug
resistance, at first MDR-TB, and later XDR-TB, mainly
caused by a particular group of strains: the Lisboa fam-
ily. Presently, this drug resistance is due almost in its
entirety to an endemic circulation of the Q1 and Lisboa3
phylogenetic clades. Present data from 24-loci (not 12-
loci) MIRU-VNTR allowed the subdivision of the
Lisbon3 cluster in two other clusters herein designated
as Lisboa3-A and –B. This data suggests two independ-
ent outbreaks, over the years, dated back to the 90s
when the discrimination of Lisboa strains was identified
by distinct rpoB mutations [8]. The Q1 spoligotyping
data has revealed that this cluster is in fact intimately
related with the B cluster identified in the 90s outbreak(unpublished data). Phylogenetic analysis based on previ-
ously published sets of SNPs [14,37] revealed that
Lisboa3 and Q1 strains formed distinct monophyletic
evolutionary clades within the SCG 5 and PGG 2. Inter-
estingly, M. tuberculosis F11 and the XDR-TB associated
KZN strains, both originating from South Africa, also
belong to SCG 5. Nevertheless a clear distinction is
highlighted in the proposed phylogeny. This distinctive-
ness is also reflected by the RD comparison, but Lisboa3,
Q1 and KZN strains appear to have an incongruent phy-
logeographic association using the RD typing. All these
strains belong to the Euro-American lineage according
to the RD classification proposed by Gagneux et al. [23].
However, the KZN strains included in the analysis
showed to be positive for RD115, associated with an
Americas/Europe sublineage, despite the fact that these
strains are a major public health concern in South
Africa, namely, the XDR-TB outbreak in KwaZulu Natal
[38,39]. The Lisboa3 and Q1 strains were on the other
hand positive for RD174, associated with a West-
African sublineage, but constitute a major public health
concern in Europe. Present knowledge recognizes that
RD174 is also associated with RDRIO, an LSP that has
initially been discovered in Rio de Janeiro, Brazil but
was later found to be widespread. Historic ties connect
Portugal, Brazil and West African Countries and a
possible ancestor for these two clades might lie in
Africa, more specifically on Portuguese Speaking African
Countries. These phylogeographic incongruences are con-
sistent with human migratory events out from, and back
into, the African continent [12]. Moreover, these results
also highlight that more is still needed to fully grasp the
genetic diversity present within the SCG5 and LAM family
as it encloses a high genetic diversity allied with a broad
geographical distribution [40].
Another question still seems pertinent as to which
selective advantages do these two clades possess allow-
ing such high prevalence in this setting especially since
other strains, e.g. pre-XDR-TB Beijing strains, also do
circulate but at an apparent lesser prevalence? TB
caused by RDRIO strains has shown to be associated
with weight loss, hemoptysis, higher bacillary loads and
progression to cavitary disease [21,41]. This deletion
encompasses several PPE genes that have shown to be a
potential source of immune variation (reviewed in
[42,43]) and hence, may constitute a pathogenic adapta-
tion strategy to immune evasion. Higher bacillary loads
are associated with a higher secondary case rate [44-46]
and if in fact the absence of these genes truly plays an
important role towards an increased virulence, or even
transmissibility, it may be a factor that has contributed
to the high prevalence of RDRIO strains in this setting
simultaneously contributing to the emergence and
spread of M/XDR-TB strains.
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tural variants that were identified and that may be clade-
specific could carry functional consequences that reflect
host adaptation and selection. The finding that a 112 bp
deletion is present among Lisboa3 clade strains, with a
more restricted distribution than RDRIO, affecting gene
PPE41 might also provide additional clues and contrib-
ute to a higher virulence or transmissibility. PPE41 has
been previously described has having an immunodomi-
nant nature and shown to activate a CD4+ and CD8+
mediated T cell response leading to an enhanced IFN-γ
response as well as induce a strong humoral response
[47,48]. The deletion found might constitute a means of
immune evasion and constitute a selective advantage
over other circulating strains. More specifically, a stron-
ger humoral response to PPE41 was found among extra-
pulmonary TB patients [48]. The selective advantage
provided by this deletion might therefore also be related
with the fact that Lisboa strains were first identified
among HIV-infected patients, which is associated with
an increase in extra-pulmonary TB.
Phylogenetic context and microevolutionary trajectory of
Lisboa3 and Q1 clades
The use of SNPs as molecular markers has contributed
to an improved understanding of the evolutionary his-
tory of the M. tuberculosis complex. In the present
study, given the availability of genomewide SNP data, a
SNP-based phylogeny was deduced from the genomic
data and, overall, the proposed phylogeny appears to be
consistent with other SNP-based phylogenies although
as already pointed out: SCG 3 does not exist as a mono-
phyletic lineage but instead as a paraphyletic one. The
original report by Filliol et al. [20] proposed a minimum
number of sixteen SNPs that allowed assignment of any
strain to an SCG but not to its subgroupings. A later er-
ratum showed that SCG 3a belonged in fact to PGG1
while SCG 3b and 3c belonged to PGG2 as confirmed
by our results. Alland et al. [37] proposed instead a set
of nine SNPs that allowed strain assignment to any SCG
and each subgroup [37].
The phylogeny constructed in the present study con-
tributes nevertheless to demonstrate the uniqueness of
Lisboa3 and Q1 strains in a global context and will com-
prise a future framework for genome-wide association
studies (GWAS).
The phylogeny proposed also enabled a microevolution-
ary perspective on the path towards MDR and XDR. As
expected, in the Lisboa3 and Q1 clades, INH resistance
was found to be mediated by double inhA promoter/struc-
tural mutations, recently described by some of us to con-
tribute to INH high-level resistance [27]. The acquisition of
inhA C-15 T mutation was found to have occurred inde-
pendently in both lineages, and in Q1 cluster it waspossible to determine that C-15 T mutation was acquired
at a first stage of INH high-level resistance development.
In Lisboa3 it was not possible to determine which mutation
appeared in the first place since no Lisboa3 isolate with a
single inhA mutation was found. Recent work by Fenner
et al. [49] suggested that inhA promoter mutations, more
specifically C-15 T mutation, might be associated with
Lineage 1 (Indo-Oceanic/SCG 1) [11,49]. Nevertheless, an-
other earlier study from Brimacombe et al. [50] showed
that SCG 1 and 5 had all the mutations of interest towards
INH resistance [50]. In our view, the fact that INH resist-
ance in both Lisboa3 and Q1 clades is associated with inhA
mutations, instead of the of the more usual KatG muta-
tions, is possibly related with selective pressures exerted by
the drug regimen itself.
The analysis of Lisboa3 subtree has further highlighted
the M/XDR evolutive process in this clade. We have
recently proposed an evolutionary path regarding drug
resistance acquisition dynamics based on the acquisition
of an eis promoter mutation as the first-step from MDR
to XDR [6]. However the SNP phylogeny proposed is
consistent with a twice and independent acquisition of
an eis promoter mutation. Given this phylogeny it is not
possible to establish any order of mutation acquisition.
Nonetheless, instead of a single event, our analysis
supports multiple development of XDR-TB in the same
phylogenetic clade. Two different transmission chains
involving strains with the RpoB S450L, instead of one,
are also more likely since it is proposed that this muta-
tion has also been acquired twice and independently [8].
Also important, he Lisboa3 XDR lineage characterized
by gyrA D94G and eis G-10A mutations (node E1) will
most likely present resistance to KAN, but not to CAP
and AMK. If drug susceptibility testing to KAN is not
included in the standard second-line drug panel of
tested drugs, the strains belonging to this lineage will
have an undetected XDR phenotype. An exception to
this is the strain FF359_98 that bears a rrs A1401G
mutation that leads to high-level KAN, AMK and CAP
resistance [51].
One striking phylogenetic incongruence was found in
two Q1 strains that lacked both second-line injectable
drug and FQ genetic resistance determinants and at the
same time sharing a recent common ancestor resistant
to these two classes of drugs. These two strains were
genotypically and phenotypically susceptible to amikacin
(AMK), capreomycin (CAP) and any of the FQs tested.
Two explanations may be considered: a phylogenetic
misplacement, although the branches had a good statis-
tical support or, these strains may descend from a
reverter ancestor. Although theoretically possible, events
such as these may be extremely rare. Only one report
has documented an in-patient reversion of an isogenic
strain from INH resistant to susceptible [52].
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The acquisition of further mutations in rpoA, rpoB or
rpoC genes following RIF resistance development was
recently demonstrated, using Salmonella as a model
organism, to have an important role in fitness compen-
sation, leading to a reduction in the doubling-time to
values closer to the wild-type [53].It as also been demon-
strated that rpoC gene has been target of convergent
evolution [54]. In our microevolutionary analysis we
have detected a RpoC mutation (K1152Q) occurring in
the same branch as a RpoB S450L (equivalent to S531L
in RpoB E. coli numbering). It is the first description of
a putative compensatory mutation within the Lisboa3
clade, contributing to the success of one of its sub-
lineages through the amelioration of the resistance fit-
ness cost [28]. RIF compensatory evolution has been the
subject of two recent studies that showed a high prevalence
of rpoA and rpoC mutations mapped to the RpoA-RpoC
interaction region [29,30,55]. The rpoC mutation described
in a Lisboa3 sub-lineage does not fall in this region, nor
was it described in these studies [29,30]. Nevertheless, two
other putative compensatory mutations mapping to the
RpoA-RpoC interaction region were found in other isolates
not belonging to the Lisboa3 or Q1 clades (Additional
file 14). The putative role of these two latter mutations is
only substantiated by the bioinformatic analysis of residue
conservation. However, the putative compensatory role of
the Lisboa3 K1152Q RpoC is further substantiated by their
co-occurrence in the same branch as the RIF resistance
determining mutation in rpoB. Furthermore, none of these
putative compensatory mutations was previously described
and may constitute novel polymorphisms associated with
molecular RIF resistance compensation [18,29,30].
RpoB mutational analysis also allowed the identification
of five putative compensatory mutations, of which one
(L731P) was found to be acquired in the Q1 clade follow-
ing RIF resistance acquisition through another rpoB muta-
tion. This latter mutation was found to be homoplasic as it
was also detected in different SCGs, which also points to-
wards the usefulness of this mutation to counteract fitness
costs imposed by the acquisition of other RIF resistance
associated mutations. Mutations outside the RIF resistance
determining region on rpoB gene have been described pre-
viously on RIF-resistant isolates with no mutations on this
region [56,57]. The mutations herein described as puta-
tively compensatory were only considered as such if a mu-
tation in the RRDR was already present providing further
support for the compensatory role of the former.
The role of compensatory mutations in other loci and
associated with compensation to resistance to other drugs
than RIF have been identified and studied, namely, muta-
tions on ahpC for INH or on rrs for second-line drug
aminoglycosides [58-60]. Nevertheless, no compensatory
mutations were identified in these genes (data not shown).Still, it is yet possible that other mechanisms under-
lying resistance or compensation might lie elsewhere in
the genome as even the role that synonymous SNPs play
in gene expression must be reckoned with. Such an
example in M. tuberculosis comes from a recent and
elegant study by Safi et al. [61] in which a synonymous
SNP on Rv3792 was found to act as an hypermorphic
mutation on a downstream gene (embC), leading to an
increase in EMB resistance [61]. In the same study,
another type of mutation was found to be a key player at
the multistep process of EMB resistance development – a
neomorphic mutation on gene Rv3806c that increased the
turnover of the decaprenylphophoryl-β-D-arabinose path-
way, which also led to an increase in EMB resistance [61].
Two other recent studies from Zhang et al. [62] and
Farhat et al. [54] also point to other genes that may be at
play and under positive selection concerning drug resist-
ance in M. tuberculosis [54,62]. It becomes clear that func-
tional characterization of the significant portion of the M.
tuberculosis genes of unknown function must catch up the
pace of high-throughput sequencing if a broader under-
standing of the genomic adaptation process is to be
obtained.
IS6110 transposition role in gene integrity and regulation
Insertion site mapping revealed a high genomic stability of
insertion sequences other than IS6110. In fact, we have
verified that only deletion events were responsible for vari-
ability regarding presence/absence of an insertion sequence
other than IS6110. On the other hand, as demonstrated in
this study IS6110 is a highly polymorphic marker, probably
due to its rapid transposition rate [63,64].
The finding that 65.5% of the IS6110 insertion sites
mapped were located intragenically is in line with previous
reports [65]. Considering that ≈ 91% of M. tuberculosis
genome is composed by coding regions [66], it highlights
the deleterious effects of transposition into certain genes
essential to viability or to the successful completion of the
pathogen’s infectious cycle. PGG1 strains, including the
Beijing strains, were found to bear a higher number of
IS6110 copies than PGG2 strains. IS6110 copy number is
presumed to be under negative selection [67], however, in
certain circumstances, it is the insertion site per se that
might provide a selective advantage and not the copy
number.
Considering the data obtained in this study, IS6110 is
unarguably the species’ most important mobile element
when considering transposition impact on genomic integ-
rity. IS6110 appears to have an important role in genomic
re-shaping towards adaptation either through localized
disruption of putative antigenic targets (e.g. PPE/PE genes)
or through its mobile promoter activity located in the
IS6110 3′ end, capable of inducing transcription or upreg-
ulating the expression of downstream genes under
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number of insertion sites to be within PPE genes and a
more reduced number of sites to be upstream of PPE
genes. PPE genes appear to have been positively selected
in pathogenic mycobacteria, have important immune and
antigenic potential, and some can induce a shift towards a
Th2-type response [42,43]. Not only the IS6110-mediated
disruption of PPE genes might constitute a mean of im-
mune evasion but it is also conceivable that upregulation
of specific PPE genes might affect the Th1/Th2 response
balance.
Remarkably, Lisboa3 and Q1 did not show any IS6110-
mediated disruption of a PPE ORF, nor did we found any
IS6110 upstream of a PPE gene. This fact perhaps demon-
strates a different mode of evolution and host adaptation
that does not require PPE gene modulation through
IS6110 transposition.
Nevertheless, the maximum distance between an IS6110
and a downstream gene so that this 3′ promoter can exert
its influence on gene expression is unknown. The results
reported by Safi et al. [68] demonstrate that an IS6110 in
M. tuberculosis 210 located 297 bp upstream of Rv1468c
was associated with a threefold increase in transcription
upon macrophage infection. Our results show that 15% of
the mapped sites are located upstream of an ORF in
proper orientation and at a distance of less than 300 bp
which, at the light of present knowledge, fulfills the neces-
sary assumptions to exert a putative upregulatory effect on
those ORFs. Also considering the diversity of ORFs inter-
rupted by IS6110 copies, gene knock out studies and as-
sessment of downstream gene expression are necessary if
a functional role for specific transposition events is to be
established.
Spoligotyping lineage association with specific IS6110
sites has already been demonstrated, highlighting the
phylogenetic informativeness of this marker [69]. Our re-
sults also support an association of specific IS6110 sites
with strain lineage at both global and local levels.
Genome-wide SNP dynamics
Notably, the comparison of the distribution of SNPs by
COG showed that Ns/S ratios vary through COG in a
lineage-dependent manner. Although, Lisboa3 and Q1 iso-
lates might be overrepresented in the analysis due to the
high prevalence in the community, we have shown that
Lisboa3 and Q1 present statistically different Ns/S ratios
from the remaining isolates. We propose that differences
in Ns/S COG might highlight different evolution strategies
selected during host-pathogen interaction and adaptation.
Moreover, an overall higher Ns/S ratio was observed
for the first quadrant and an overall lower Ns/S ratio
was observed for the second quadrant revealing hetero-
geneous Ns/S ratios negatively correlated with the Tv/Ts
ratio. The biochemical nature behind this Tv/Ts ratioheterogeneity requires further studies as it may be driv-
ing localized higher non-synonymous mutation rates
with functional impact on strain evolution. The precise
genes affected by non-synonymous mutations within
these COG categories merit further studies as each
COG includes a considerable number of genes, that mu-
tated might enhance the transmissibility or drug resist-
ance, and should be analyzed in a systems biology
perspective using in silico models [70-72].
The finding that terminal branches of the subtrees
analyzed had lower Ns/S ratios than the inner branches
was contrary to the findings of Namouchi et al. [36].
Namouchi et al. suggested that non-synonymous changes
might be purged by natural selection yielding higher Ns/S
ratios. However, an opposite view is also possible: non-
synonymous mutations are favored by natural selection
yielding the same higher Ns/S ratio, especially as a mean
of adaptation in an organism devoid, or with low, horizon-
tal gene transfer such as M. tuberculosis [73,74]. From our
data, we can say that non-synonymous mutations may be
favored in the inner branches of both subtrees as a mean
to develop and adapt to drug resistance, yielding a higher
Ns/S ratio that is consistent with a reduced purifying selec-
tion [12]. Nevertheless, the differences between the results
from both studies might lie in the fact that the Ns/S ratio
analysis herein presented was performed for two sets of
strains that are in a much more closer time frame in order
to understand microevolution within two clades.
WGS and molecular epidemiology
In the present study we have shown that in Lisbon,
Portugal, where the MDR-TB situation had already esca-
lated to a XDR-TB situation, it is mainly caused by trans-
mission of two unique phylogenetic clades. We have
previously shown that XDR-TB was already a reality in
Portugal during the 1990s [6] but noteworthy, the data
from the present study clearly shows that these strains be-
long to the same phylogenetic Lisboa3 M/XDR sublineages
that are still presently in circulation. The uniqueness of
these strains was revealed by a distinct phylogenetic place-
ment within SCG 5.
The Lisboa3 clade belongs to a much broader group of
strains that usually share at least 95% of MIRU-VNTR
pattern similarity: the Lisboa family [7]. One of the
future goals is to better understand the populational
structure of this family of strains, from which the Lis-
boa3 clade has differentiated, as strains belonging to this
family have previously shown the potential to evolve to
MDR-TB [4].
Another important point coming from the present stu-
dent is the utility of WGS for epidemiological surveillance
and strain typing. WGS presents an advantage over the
classical typing methods (RFLP-IS6110, Spoligotyping or
MIRU-VNTR) as it enables picturing transmission at a
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using well described models of molecular evolution. In the
present study, WGS allowed strain discrimination within
MIRU-VNTR clusters and distinguish between three inde-
pendent Lisboa3 MDR sub-clades. Despite the technical
difficulties in data analysis, as WGS costs converge to-
wards the cost of MIRU-VNTR, the former is likely to
replace MIRU-VNTR as the gold-standard for molecular
epidemiological surveillance and strain typing. WGS can
also enable more focused contact tracing by reducing the
number of plausible genomically linked cases to investi-
gate, leading to an improved case detection. WGS-assisted
routine surveillance is still far away for many settings, but
as this technology becomes gradually available to the
mycobacteriology laboratory it will also be expected a
greater understanding of TB transmission. In a recent
study, Walker et al. have defined a threshold of 12 SNPs
of difference, above which recent transmission can be ex-
cluded [75]. In our study, the number of unique SNPs to
each isolate determined for the Lisboa3 and Q1 clades are
consistent with ongoing recent transmission. This finding
allied with the genomic uniqueness of these strains are of
special importance not only locally but in a macro-
epidemiological context. It is likely that these strains may
spread to other parts of the world, due to increasing global
travel and migratory waves, and be the cause of additional
public health concern [76-78]. A recent report of an
RDRIO strain recovered from a remote location in Tibet
alerts to this possibility [79].
It is also worth having in consideration that the host res-
iding bacilli population has a certain degree of heterogen-
eity that can be overlooked through WGS but nonetheless
lead to a higher than expected genomic difference after
transmission. Similarly, selection during drug treatment
might also artificially extend genomic distances. In this
regard, classical genotyping using more stable markers
might prove useful. The present study also stresses the
need of further genomic studies in order to contribute to a
M. tuberculosis genome-wide evolutive scenario, represen-
tative of different settings.
This, together with clinical data, will ultimately enable
GWAS with a positive impact in TB management.
Conclusions
In conclusion, it was found that the two main genetic clus-
ters responsible for the great majority of MDR-TB in
Portugal form two monophyletic clades (Lisboa3 and Q1)
that denote sequential resistance amplification and/or inde-
pendent resistance acquisition. The data supports the
notion of ongoing MDR-TB transmission and endemicity
associated with Lisboa3 and Q1 clades. The results obtained
also support notion of a higher genomic diversity than the
one usually associated with M. tuberculosis, mostly acquired
through genome downsizing and non-synonymous SNPs.Different deletions were found to be specific to a number of
lineages, of which some may carry functional consequences.
Specifically, the 112 bp deletion on PPE41 gene that, found
among Lisboa3 strains, may provide a selective advantage
for these strains. Different SNP acquisition dynamics were
also identified between the two clades which are suggestive
of different adaptation strategies in which the transposition
of IS6110 may also have an important role in modulating
gene expression and integrity.
Methods
Isolates and genetic data
The study consists of 56M. tuberculosis clinical isolates
(source: 55 Lisbon, 1 Oporto) recovered from laboratories
and hospital units across Lisbon Health region. This set of
isolates comprises a convenience sample of M. tuberculosis
clinical isolates received for genotypic analysis at the
Mycobacteria Laboratory from the Faculty of Pharmacy of
the University of Lisbon. The sample is composed by drug
resistant isolates plus additional susceptible isolates found
to be genetically close (MIRU-VNTR) to the drug resistant
isolates. All isolates underwent drug susceptibility testing
for INH, RIF, STP, EMB and PZA and second-line drugs
using standard methods (see [4]). DNA extraction was
performed from culture growth on Lowenstein-Jensen
medium slants using the cetyl trimethylammonium brom-
ide methodology [80]. The DNA was used in genotyping
by the 24-loci MIRU-VNTR method (see previous work,
[81]). Extracted DNA was also subjected to whole-genome
(101 bp paired end) sequencing at the KAUST genomics
facility using the Illumina HiSeq 2000 platform (500 bp
insert size). We also complemented this data using se-
quences in the public domain (F11, CDC1551, KZN1435,
KZN4207, KZN605, KZN_R506, KZN_V2475, UT205
RGTB327, RGTB423, CCDC5180, CCDC5079, CTRI-2,
BTB05_552, BTB05_559, S96_129, HN878, R1207, and
X122 (all from the NCBI database).
Genomic variant detection
The raw Illumina sequencing data was aligned to the
H37Rv reference genome using the Burrows-Wheeler
Alignment Tool v.0.6.1, yielding high coverage data for
all isolates (mean read depth per position, mean 249.9,
range 44–1411 fold; mean 99.1% genome covered, range
98.6 - 99.9%) (Table 1) [82]. Single nucleotide polymor-
phisms (SNPs) and small indels (<30 bp) were called
using SAMtools software (v0.1.18) [83]. Other small
indels (<100 bp) were detected using the software Pindel
[84]. Only variants supported by at least ten sequence
reads were considered. Detection of larger structural var-
iants was performed using the SVMerge v1.2 pipeline
combining Pindel v0.2.4 t, BreakDancer v1.1 Cpp pack-
age and, SECluster analysis outputs [85,86]. Structural
variant detection was done for each isolate alone and
Perdigão et al. BMC Genomics 2014, 15:991 Page 16 of 20
http://www.biomedcentral.com/1471-2164/15/991validation was achieved using comparison with local de
novo assembly using Velvet [87]. Loci reported to be as-
sociated with regional differences [22,23,88] were identi-
fied using the alignments and coverage.
For insertion sequence (IS) mapping, reads containing
specific oligonucleotide sequence of both 5′ and 3′ ex-
tremities (listed in Additional file 22) were extracted
and, flanking genomic regions of interest concatenated in
FASTA format producing one file for each extremity for
each strain. Local BLAST analysis (standalone NCBI
BLAST v.2.2.27+) was carried out for each file against M.
tuberculosis H37Rv reference genome, minimum support-
ing read depth used to as a quality filter (10 for isolates
with >500 fold coverage, 2 for the remaining). For IS6110
BLAST hits, a mapping quality classification scheme was
established consisting in high confidence, medium confi-
dence and lesser confidence sites. Paired sites correspond-
ing to mapping of both 5′ and 3′ ends in all isolates on
which it occurred were classified as high confidence sites.
Paired insertion sites for which both ends were mapped in
at least 50% of the isolates on which they were found to
occur were considered of medium confidence. Insertion
sites in which only one end of the IS6110 was mapped
were considered of lesser confidence. Furthermore, inser-
tion site hits mapped to M. tuberculosis H37Rv were ex-
cluded to avoid repetitive mapping.Other bioinformatics
The genomic data of publicly available M. tuberculosis
strains (format FASTA) were included in the analysis
through conversion to FASTQ format reads using the
program dwgsim v.0.1.10, and mapped and analyzed as
described above. When necessary, DNA sequence align-
ment was performed using the CLC Sequence Viewer
v7.6.1 (CLC bio®, Aarhus N, Denmark) and visualized in
BioEdit v7.1.3.0 (T. Hall).
A MIRU-VNTR-based dendrogram was constructed in
the public MIRU-VNTRplus database using the Dsw meas-
ure of genetic distance for tandem repeat loci [89] and the
Unweighted Pair Group Method with Arithmetic Averages
(UPGMA) clustering method. Spoligotyping profile was
inferred from raw read data using the SpolPred software
followed by comparison to the SITVIT WEB database
[40,90]. A phylogenetic tree based on SNPs was constructed
using Seaview 4.3.5 [91] using the Maximum Likelihood
method. The analysis involved 76 nucleotide sequences
with a total of 11271 sites in the final dataset. Tree topology
was tested using the most recent approximate Likelihood
Ratio Test (aLRT) as an alternative to bootstrap.
Putative impact of selected compensatory mutations
on protein function was assessed through the use of
SIFT scores (available at http://sift.jcvi.org/) [31] com-
puted from the query alignment against UniRef90database hits (with less than 90% identity, with a median
sequence conservation equal to 3.00).
Any statistical analysis was conducted using the SPSS
software.
Data access
All sequencing data have been submitted to the European
Nucleotide Archive (http://www.ebi.ac.uk/ena/) under study
accession number ERP002611. Phylogenetic data (tree and
alignment matrix) have been submitted to TreeBase under
Study ID no. 16158 (URL: http://treebase.org/treebase-web/
home.html).
Additional files
Additional file 1: Boxplot graph showing the different types of SNP
mutations.
Additional file 2: Distribution of RD deletions found across the
analyzed genomes of 75 M. tuberculosis isolates. RD absence is
assigned with a black square and, Lisboa3 and Q1 clade isolates are
highlighted in red and blue, respectively. Column and line totals account
for the total number of RDs in column or line, respectively.
Additional file 3: Structural variability among sequenced strains.
Additional file 4: List of short deletions (<100 bp) found among the
group of 75 clinical isolates. Black squares indicate deletion detection.
MIRU-VNTR cluster indicates the 24-loci MIRU-VNTR cluster of any given
isolate, except if non-clustered (NC) or not determined (nd). Line and
column totals indicate total column/line count of deletions. Isolates
highlighted in red and blue belong to Lisboa3 and Q1 clade, respectively.
Additional file 5: List of short insertions (<100 bp) found among
the group of 75 clinical isolates. Black squares indicate insertion
detection. MIRU-VNTR cluster indicates the 24-loci MIRU-VNTR cluster of
any given isolate, except if non-clustered (NC) or not determined (nd).
Line and column totals indicate total column/line count of insertions.
Isolates highlighted in red and blue belong to Lisboa3 and Q1 clade,
respectively.
Additional file 6: List of selected clade-defining candidate SVs, its
position, size and affected ORFs. Each clade-defining candidate SV was
selected based on phylogenetic congruence and presence in all members
of the specified clade.
Additional file 7: Types and number of large SVs (≥100 bp) found
among the 75 analyzed isolates using the SVMerge pipeline and
local assembly validation.
Additional file 8: List of SV types found amoing the 75 clinical isolates
group using the SVMerge pipeline and excluding copy number gain
hits. SV type includes: deletions (DEL); completely (INSi) and incompletely
(INS) reconstructed insertions; simple inversions (INV) and complex inversions
(INVCOMPLEX); deletions plus insertions (DELINS); and, inversions plus
deletions (INVDEL) or plus insertions (INVINS). Black squares are indicative of
SV detection. MIRU-VNTR cluster indicates the 24-loci MIRU-VNTR cluster of
any given isolate, except if non-clustered (NC) or not determined (nd). Line
and column totals indicate total column/line count of SVs. Isolates
highlighted in red and blue belong to Lisboa3 and Q1 clade, respectively.
Additional file 9: Number of mutations categorized by structural
and functional effect type found along specified branches of the
Lisboa3 subtree.
Additional file 10: Number of mutations categorized by structural
and functional effect type found along specified branches of the Q1
subtree.
Additional file 11: Intra-clade SNP diversity and uniqueness.
Number of SNPs unique to each isolate and percentage of total
SNPs detected. Represented below each clade designation are: the
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http://www.biomedcentral.com/1471-2164/15/991number of SNPs that represents the total pool of SNPs shared by all
isolates belonging to the respective clade; and, the range of the total
percentage that this latter SNP pool count comprises from the total
percentage of the isolates’ detected SNPs.
Additional file 12: Mutations found to be acquired along node-
delimited branches in the Lisboa3 subtree. Position, Reference Sequence
and Mutated Sequence are derived from the VCF format.
Additional file 13: Mutations found to be acquired along node-
delimited branches in the Q1 subtree. Position, Reference Sequence
and Mutated Sequence are derived from the VCF format.
Additional file 14: Molecular model of Escherichia coli core RNA
polymerase (Opalka et al. [55]) (RCSB Protein Data Bank ref. 3 LU0)
showing the homologous RpoC residues found to be involved in
putative RIF resistance compensation in M. tuberculosis. The
different RNA polymerase subunits are shown: Alpha/RpoA (blue chain),
Beta/RpoB (brown chain), Beta’/RpoC (green chain) and Omega/RpoZ
(grey chain). The RpoC highlighted residues, in red, Gly367, Trp409 and
Lys1251 are homologous to the RpoC residues Gly442, Trp484 and
Lys1152 from M. tuberculosis, respectively.
Additional file 15: Genomic mapping of Insertion Sequnces relative
to the genome of M. tuberculosis H37Rv. Black squares indicate
presence of the IS at the specified locations by mapping of both 5′ and
3′ ends, if both ends were used in mapping analysis. MIRU-VNTR cluster
indicates the 24-loci MIRU-VNTR cluster of any given isolate, except if
non-clustered (NC) or not determined (nd). Grey quares indicate mapping
of only one end.
Additional file 16: Mapped positions of IS6110 found across the
genomes of the 75 analyzed M. tuberculosis clinical isolates in relation
to M. tuberculosis H37Rv. Each mapped position shown refers to a IS6110
end from which the genomic position of insertion was deduced, referred on
the Mapped End column. Chain column shows the chain coding for IS6110
copy in question and consequently, its orientation. Confidence column
corresponds to the quality/confidence level classification explained in the
Materials and Methods section. ORF column shows: the affected ORF in case
of an intragenic insertion site; intergenic if the site is intergenic and mapped
IS is not on the proper orientation to exert a putative upregulatory effect on
an ORF located downstream of the IS 3′ end; or, the preffix up indicating that
the mapped IS is upstream and in the same orientation of a downstream
ORF, followed by a number indicating the distance to the downstream ORF
and, followed by the ORF designation, gene or feature designation. Black
squares indicate IS6110 copies mapped at both 5′ and 3′ end; grey squares
indicate IS6110 copies that only the mapped end indicated in the Mapped
End column was mapped; and, yellow squares indicate IS6110 copies on
which the only mapped end is the other end than the one indicated in the
Mapped End column. MIRU-VNTR cluster indicates the 24-loci MIRU-VNTR
cluster of any given isolate, except if non-clustered (NC) or not determined
(nd). Column and line totals account for the number of IS6110 copies mapped
on each line and column, respectively. Isolates highlighted in red and blue
belong to Lisboa3 and Q1 clades, respectively.
Additional file 17: Multiple comparison test results upon comparison
of mean overall Ns/S and Tv/Ts ratios for four groups of strains:
Lisboa3, Q1, Beijing clades and, other non clustered strains (NC).
Significant differences at the 0.05 level are highlighted in bold.
Additional file 18: Multiple comparison test results upon comparison
of mean Ns/S and Tv/Ts ratios across the four genomic quadrants.
Significant differences at the 0.05 level are highlighted in bold.
Additional file 19: Multiple comparison test results upon
comparison of mean Ns/S and Tv/Ts ratios across the four genomic
quadrants for four groups of strains: Lisboa3, Q1, Beijing clades
and, other non clustered strains (NC). Significant differences at the
0.05 level are highlighted in bold.
Additional file 20: Multiple comparison test results upon comparison
of mean Ns/S ratios across the different COGs for four groups of
strains: Lisboa3, Q1, Beijing clades and, other non clustered strains
(NC). Significant differences at the 0.05 level are highlighted in bold.
Additional file 21: Multiple comparison test results upon
comparison of mean Tv/Ts ratios across the different COGs for fourgroups of strains: Lisboa3, Q1, Beijing clades and, other non
clustered strains (NC). Significant differences at the 0.05 level are
highlighted in bold.
Additional file 22: End sequences from the different ISs used as
probes to extract reads for mapping analysis.
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